Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Sees Significant Drop in Short Interest

Jasper Therapeutics, Inc. (NASDAQ:JSPRWGet Free Report) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 16,400 shares, a decline of 18.0% from the October 31st total of 20,000 shares. Based on an average trading volume of 5,000 shares, the short-interest ratio is currently 3.3 days.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock traded up $0.02 during trading on Monday, hitting $0.22. 127 shares of the company’s stock traded hands, compared to its average volume of 16,684. Jasper Therapeutics has a twelve month low of $0.04 and a twelve month high of $0.38. The firm’s fifty day moving average price is $0.21 and its 200 day moving average price is $0.21.

About Jasper Therapeutics

(Get Free Report)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

See Also

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.